TABLE 3.

Levels of serum IgG to antigens in OMVs from strain NZ98/254 measured on immunoblots before vaccination and after the third dose of MeNZB and MenBvaca

OMV antigenIgG binding intensityb (kAU) for MeNZB groupP for MeNZB groupIgG binding intensityb (kAU) for MenBvac groupP for MenBvac groupP for postresponse comparison
Prevaccination seraPostvaccination seraPrevaccination seraPostvaccination sera
Omp850 (0-1.4)1.6 (0-7.9)<0.0010 (0-1.4)3.2 (0-9.2)<0.0010.042
FetA0.4 (0-15.2)1.7 (0-15.4)0.0010 (0-15.9)0 (0-19.5)NS0.044
PorA4.3 (2.2-9.1)13.0 (3.9-22.7)<0.0014.4 (2.1-12.6)6.7 (2.4-20.4)<0.001NS
PorB6.5 (0-23.7)17.5 (5.0-48.8)<0.0016.7 (5.2-25.7)11.6 (4.6-19.4)0.0050.015
FbpA0 (0-14.7)12.3 (0-18.7)0.0010 (0-11.0)4.1 (0-16.8)0.0020.029
RmpM3.4 (0-7.0)6.3 (2.3-14.8)<0.0013.2 (1.3-12.0)5.6 (2.8-17.2)<0.001NS
OpcA0 (0-2.7)0 (0-9.2)0.0200 (0-6.2)1.8 (0-14.0)0.004NS
OpaJcNDeNDNDND
NspA1.6 (0-16.1)2.4 (0-13.6)NS0 (0-2.4)0 (0-3.1)NS0.008
LPSd0 (0-29.5)4.9 (0-41.3)<0.0010 (0-9.3)2.9 (0-24.8)0.002NS
  • a Pre- and postvaccination sera from 24 and 16 individuals receiving MeNZB and MenBvac, respectively, were analyzed.

  • b IgG binding intensities were obtained by scanning; the values are medians, with ranges given in parentheses. The AUs were rounded off to the nearest 100 integer. NS, no significant difference.

  • c OpaJ is not detected in MeNZB.

  • d LPS antibody responses are the sums for the L3 and L1 bands.

  • e ND, not determined.